Bevantolol HCl
CAS: 42864-78-8
Rif. 3D-FB36830
5g | Fuori produzione | ||
10g | Fuori produzione | ||
25g | Fuori produzione | ||
50g | Fuori produzione | ||
100g | Fuori produzione |
Informazioni sul prodotto
- (±)-1-((2-(3,4-Dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol Hydrochloride
- (±)-1-((3,4-Dimethoxyphenethyl)amino)-3-(m-tolyloxy)-2-propanol Hydrochloride
- 1-{[2-(3,4-Dimethoxyphenyl)ethyl]amino}-3-(3-methylphenoxy)propan-2-ol hydrochloride (1:1)
- 2-Propanol, 1-[[2-(3,4-Dimethoxyphenyl)Ethyl]Amino]-3-(3-Methylphenoxy)-, Hydrochloride (1:1)
- 2-Propanol, 1-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-methylphenoxy)-, hydrochloride
- Ci 775
- Cl 775
- Nc 1400
- Ranestol
- Sentiloc
- Vedi altri sinonimi
- Vantol
- Bevantolol hydrochloride
Bevantolol HCl is a beta-adrenergic receptor antagonist that inhibits the binding of norepinephrine to the β1-adrenergic receptor. It is used for the treatment of metabolic disorders, such as hyperglycemia and hyperlipidemia, which are associated with diabetes mellitus. Bevantolol HCl has also been shown to have some effects on cardiac function, including lowering heart rate and increasing contractility. It binds to the ryanodine receptor, an intracellular calcium release channel in the sarcoplasmic reticulum of muscle cells, which may be related to its effects on locomotion. Bevantolol HCl also inhibits platelet aggregation and acts as an inhibitor of PCSK9.